NCT03084757View on ClinicalTrials.gov

SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)

NACompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

May 26, 2017

Primary Completion Date

October 20, 2022

Study Completion Date

May 31, 2024

Conditions

CancerSolid Tumor, Adult

Interventions

DIAGNOSTIC_TEST

research of druggable molecular alterations on tumor biopsy

The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations

Trial Locations (4)

33076

Institut Bergonié, Bordeaux

69373

Centre LEON BERARD, Lyon

75005

Institut Curie, Paris

92210

Institut Curie Hôpital René Huguenin, Saint-Cloud

All Listed Sponsors

lead

Institut Curie

OTHER

NCT03084757 - SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02) | Biotech Hunter | Biotech Hunter